Edition:
India

Tonix Pharmaceuticals Holding Corp (TNXP.OQ)

TNXP.OQ on NASDAQ Stock Exchange Global Market

0.65USD
24 Sep 2018
Change (% chg)

-- (--)
Prev Close
$0.65
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
81,955
52-wk High
$5.10
52-wk Low
$0.60

Chart for

About

Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company. The Company's drug development programs are directed toward disorders affecting the central nervous system (CNS), and include fibromyalgia (FM), and post-traumatic stress disorder (PTSD). It is focused on developing a portfolio of product candidates,... (more)

Overall

Beta: 2.98
Market Cap(Mil.): $36.27
Shares Outstanding(Mil.): 7.51
Dividend: --
Yield (%): --

Financials

BRIEF-Tonix Pharmaceuticals Holding Says Files For Mixed Shelf Of Up To $75 Mln

* TONIX PHARMACEUTICALS HOLDING SAYS FILES FOR MIXED SHELF OF UP TO $75 MILLION - SEC FILING Source text for Eikon: (http://bit.ly/2KqLRZ4) Further company coverage:

02 May 2018

BRIEF-Tonix Pharmaceuticals Receives IND Clearance By U.S. FDA For TNX-102 SL

* TONIX PHARMACEUTICALS RECEIVES IND CLEARANCE BY U.S. FDA FOR TNX-102 SL IN AGITATION IN ALZHEIMER’S DISEASE Source text for Eikon: Further company coverage:

01 May 2018

BRIEF-Tonix Pharmaceuticals To Present FDA Breakthrough Therapy Designated PTSD Program At Microcap Conference

* DESIGNATED PTSD PROGRAM AT THE MICROCAP CONFERENCE IN NEW YORK

04 Apr 2018

BRIEF-Tonix Pharma Ready To File For Approval Of PTSD Treatment In 2019 Based On Study Data

* TONIX PHARMACEUTICALS ACHIEVES 50 PERCENT ENROLLMENT IN PHASE 3 TRIAL OF FDA-DESIGNATED BREAKTHROUGH THERAPY TONMYA® (CYCLOBENZAPRINE HCL SUBLINGUAL TABLETS) FOR THE TREATMENT OF PTSD

03 Apr 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $140.47 --
Pfizer Inc. (PFE.N) $43.93 --
Novartis AG (NOVN.S) CHF82.66 +0.86
AstraZeneca plc (AZN.L) 5,706.00 +54.00
GlaxoSmithKline plc (GSK.L) 1,527.72 +4.92

Earnings vs. Estimates